Advanced Accelerator Application SA(ADR) (AAAP) is Initiated by Wells Fargo to Outperform

Advanced Accelerator Application SA(ADR) (AAAP) was Initiated by Wells Fargo to “Outperform”. Wells Fargo advised their investors in a research report released on Oct 18, 2016.

Advanced Accelerator Applications SA is a radiopharmaceutical company that develops produces and sells molecular nuclear medicine (MNM) diagnostic and therapeutic products. The Company’s lead therapeutic candidate Lutathera is being developed for the treatment of midgut neuroendocrine tumors (NETs). The Company has a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. Its products in clinical development include Lutathera Somakit and Annexin V-128. The Company’s commercial products include Gluscan /Gluscan 500/Barnascan IASOflu IASOdopa IASOcholine MIBITEC/Adamibi and Leukokit. Lutathera is a solution of a Lu-177-labeled analogue of somatostatin a hormone that acts as a regulator of the endocrine system. Somakit is the Company’s companion PET diagnostic product candidate for Lutathera. Annexin V-128 is a SPECT diagnostic candidate for the assessment of apoptotic and necrotic processes.

Advanced Accelerator Application SA(ADR)

Leave a Reply

Advanced Accelerator Application SA(ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Advanced Accelerator Application SA(ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.